Bernstein initiated coverage of Galapagos (GLPG) with a Market Perform rating and EUR 27.90 price target The firm says the company has transformed itself from a biotech with a cell therapy pipeline into an investment company that seeks to build biotech businesses. Galapagos has undergone a “complete reset,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Galapagos price target raised to $32 from $28 at RBC Capital
- Galapagos NV Reports Strategic Shift and Financial Results
- Galapagos NV Earnings Call: Strategic Shifts Amid Challenges
- Galapagos NV to Wind Down Cell Therapy Business Amid Strategic Shift
- Galapagos to Present Promising CAR-T Cell Therapy Data at ASH 2025